2024³â 12¿ù 24ÀÏ È­¿äÀÏ
 
 
  ÇöÀçÀ§Ä¡ > ´º½ºÁö´åÄÄ > Science & Technology

·£¼¶¿þ¾îºÎÅÍ µÅÁöµµ»ì±îÁö... ³ë·ÃÇØÁø »ç±âÇà°¢

 

Á¤Ä¡

 

°æÁ¦

 

»çȸ

 

»ýÈ°

 

¹®È­

 

±¹Á¦

 

°úÇбâ¼ú

 

¿¬¿¹

 

½ºÆ÷Ã÷

 

ÀÚµ¿Â÷

 

ºÎµ¿»ê

 

°æ¿µ

 

¿µ¾÷

 

¹Ìµð¾î

 

½Å»óÇ°

 

±³À°

 

ÇÐȸ

 

½Å°£

 

°øÁö»çÇ×

 

Ä®·³

 

Ä·ÆäÀÎ
Çѻ츲 ¡®¿ì¸®´Â ÇѽҸ²¡¯ ½Ò ¼Òºñ Ä·ÆäÀÎ ½Ã...
1000¸¸¿øÂ¥¸® Àΰø¿Í¿ì, °Ç°­º¸Çè Áö¿ø ¡®Æò...
- - - - - - -
 

Parse Biosciences Launches Trailmaker Data Analysis Platform to Simplify Single Cell Sequencing

New cloud platform facilitates streamlined, end-to-end analysis of single cell data
´º½ºÀÏÀÚ: 2024-06-06

SEATTLE -- Parse Biosciences, a leading provider of accessible and scalable single cell sequencing solutions, today announced the availability of Trailmaker™, its user-friendly cloud platform purpose-built for single cell data analysis. Fast, scalable, and capable of providing end-to-end analysis, Trailmaker removes common analysis barriers, rapidly transforming single cell data into biological insights.

Single-cell RNA sequencing (scRNA-seq) offers researchers comprehensive insights into biological systems and finds applications in diverse fields such as developmental biology, oncology, and immunology. As scRNA-seq becomes more widely adopted and experiment sizes scale, there is a growing need for accessible data analysis methods that help researchers easily generate biological insights.

“Traditional single cell data analysis presents a number of challenges, including data processing, visualization, data integration and interpretation, as well as a shortage of experts who can process the data,” noted Parse Biosciences co-founder and CTO Charlie Roco. “Our goal is to make single cell research easier, more cost effective, and more scalable. With Trailmaker, any scientist can easily process and analyze their single cell data, enabling them to draw insights from their experiments and projects more quickly.”

Trailmaker can take unprocessed sequencing files (FASTQ) generated from Evercode Whole Transcriptome kits and provide downstream data visualizations and publication-ready figures in a few simple clicks, without the need for a single line of code.

The new platform is a direct result of Parse Biosciences’ acquisition of Biomage in early 2024. Already in use by over 4,500 researchers, the rebranded and enhanced data analysis platform is now officially available to Parse Biosciences’ customers and all academic researchers free of charge.

Parse Biosciences will be discussing the capabilities of Trailmaker at this year’s European Society of Human Genetics Meeting in Berlin, Germany, June 1-5.



 Àüü´º½º¸ñ·ÏÀ¸·Î

The Next Gen of AI Awaits, GIGABYTE Sets the Benchmark for HPC at CES 2025
SpaceRISE Signs Concession Contract to Deliver Europe¡¯s IRIS©÷ Connectivity Network
Boomi Boosts Data Management Capabilities With Acquisition of Modern Data Integration Provider Rivery
Korean Robotaxi Startup Sonnet.AI Secures Level 4 Autonomous Shuttles Certification
KIOXIA NVMe SSD Cryptographic Module Achieves FIPS 140-3 Level 2 Validation
CHMP Recommends Approval of Galderma¡¯s Nemolizumab for Moderate-to-Severe Atopic Dermatitis
BrightPath Bio and Cellistic Announced Process Development and Manufacturing Collaboration

 

Parse Biosciences Launches Evercode Mouse BCR to Support Antibody Engi...
PDC*line Pharma Presents Primary Clinical Results From Phase I/II Tria...
Tanner Pharma Expands Global Access to Botensilimab and Balstilimab Th...
Abu Dhabi¡¯s Technology Innovation Institute Inaugurates Open-Source A...
DNP Achieves Fine Pattern Resolution on EUV Lithography Photomasks for...
Octapharma Injects Efficiency Into Its Supply Chain With Kinaxis
Kioxia Develops OCTRAM (Oxide-Semiconductor Channel Transistor DRAM) T...

 


°øÁö»çÇ×
´º½ºÁö ÇÑÀÚÇ¥±â 'ãæÚ¤ó¢'
´º½º±×·ì Á¤º¸ ¹Ìµð¾î ºÎ¹® »óÇ¥µî·Ï
¾ËÇÁ·Ò °è¿­ »óÇ¥, »óÇ¥µî·Ï ¿Ï·á
¾Ë¶ã°Ç¼³, »óÇ¥µî·Ï ¿Ï·á
Á¸Â÷´åÄÄ, ±Û²Ã º¯°æ »óÇ¥µî·Ï ¿Ï·á

 

ȸ»ç¼Ò°³ | ÀÎÀçä¿ë | ÀÌ¿ë¾à°ü | °³ÀÎÁ¤º¸Ãë±Þ¹æħ | û¼Ò³âº¸È£Á¤Ã¥ | Ã¥ÀÓÇÑ°è¿Í ¹ýÀû°íÁö | À̸ÞÀÏÁÖ¼Ò¹«´Ü¼öÁý°ÅºÎ | °í°´¼¾ÅÍ

±â»çÁ¦º¸ À̸ÞÀÏ news@newsji.com, ÀüÈ­ 050 2222 0002, Æѽº 050 2222 0111, ÁÖ¼Ò : ¼­¿ï ±¸·Î±¸ °¡¸¶»ê·Î 27±æ 60 1-37È£

ÀÎÅͳݴº½º¼­ºñ½º»ç¾÷µî·Ï : ¼­¿ï ÀÚ00447, µî·ÏÀÏÀÚ : 2013.12.23., ´º½º¹è¿­ ¹× û¼Ò³âº¸È£ÀÇ Ã¥ÀÓ : ´ëÇ¥ CEO

Copyright ¨Ï All rights reserved..